Anti-cancer compositions and methods
Anti-cancer compositions and methods are described including one or more compounds having the structural formula I: R2-R—R1, where R is phenyl, where R1 is (CH 2 ) n —Se—C(═NH)—NH 2 , where R2 is (CH 2 ) n —Se—C(═NH)—NH 2 or R2 is H, and where each n is independently 2, 3, 4, 5, 6, 7, or 8. Methods of treating a subject are provided according to embodiments of the present invention which include administering a therapeutically effective amount of a composition including one or more compounds having the structural formula I to a subject having a condition characterized by Akt dysregulation. Administering a therapeutically effective amount of a composition including one or more compounds having the structural formula I to a subject detectably increases apoptosis and/or decreases proliferation of cancer cells, particularly cancer cells characterized by Akt dysregulation. Compositions of the present invention inhibit Akt enzymes, iNOS, and increase MAP kinase activity such that cancer cells contacted with the compositions are inhibited.
1. A method of treating a subject having melanoma, comprising:
administering a therapeutically effective amount of a composition comprising a compound having the structural formula:
R2-R—R1, where R is phenyl, where R1 is (CH 2 ) n —Se—C(═NH)—NH 2 , where R2 is (CH 2 ) n —Se—C(═NH)—NH 2 or R2 is H, and where each n is independently an integer in the range of 2-8, inclusive.
2. The method of claim 1 , wherein the composition comprises a compound having the structural formula selected from the group consisting of:
where each n is independently an integer in the range of 2-8, inclusive;
3. The method of claim 1 , wherein the composition is formulated for topical application.
4. The method of claim 1 wherein the subject is human.
5. The method of claim 1 , wherein the melanoma is characterized by dysregulation of Akt, iNOS or MAP kinase.
6. The method of claim 1 , wherein the melanoma is characterized by dysregulation of Akt3.
7. The method of claim 1 , wherein administering the therapeutically effective amount of the composition to a subject detectably increases apoptosis and/or decreases proliferation of cells of the melanoma.
8. The method of claim 1 , further comprising administration of an adjunct anti-cancer treatment.
9. The method of claim 1 , wherein the composition is administered topically.